The short answer
On 10 August 2026 the MHRA authorised orforglipron, marketed as Foundayo by Eli Lilly, making the United Kingdom the first country in Europe to license the tablet. It is a once-daily oral GLP-1 receptor agonist approved for weight management and for glycaemic control in type 2 diabetes. It is not yet available on the NHS.
Key facts
- Authorised
- 10 August 2026 (MHRA)
- Brand name
- Foundayo
- Developer
- Eli Lilly and Company
- Class
- Oral small-molecule GLP-1 receptor agonist
- Administration
- Once-daily tablet, no food or water restrictions
- First in Europe
- Yes (no EU regulator had authorised it at the time)
- NHS status
- Not available; NICE guidance now expected on 27 January 2027
What exactly was approved?
The MHRA granted marketing authorisation for orforglipron under the brand name Foundayo on 10 August 2026. The authorisation covers two distinct populations. The first is weight loss and weight maintenance in adults with a BMI of 30 or above, or a BMI between 27 and 30 where at least one weight-related comorbidity is present, used alongside a reduced-calorie diet and increased physical activity. The second is improving glycaemic control in adults with insufficiently controlled type 2 diabetes.
Why the approval was treated as significant
Two features made this a widely covered decision rather than a routine authorisation. The UK moved ahead of the European Medicines Agency, which is unusual for a product of this profile and was framed by the MHRA as a deliberate regulatory position. Beyond that, orforglipron is taken as an ordinary tablet at any time of day, with no fasting window and no requirement to take it with a set volume of water, a practical difference from the oral peptide products that preceded it.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What the Phase 3 data showed
The pivotal obesity data were published in the New England Journal of Medicine on 16 September 2025. Over 72 weeks, mean weight reduction was 7.5% on 6 mg, 8.4% on 12 mg and 11.2% on 36 mg, against 2.1% on placebo. A separate study, ACHIEVE-3, reported in February 2026 that orforglipron produced greater weight reduction than oral semaglutide in adults with insufficiently controlled type 2 diabetes.
How it compares with the injectable incretins
It does not match them on magnitude, and the trial data do not claim to. The headline reductions from tirzepatide and from retatrutide's Phase 3 programme are substantially larger. Orforglipron's case rests on route of administration rather than effect size: an oral tablet with no absorption enhancer and no dosing ritual addresses a different problem from the one a weekly injection solves.
Reported adverse effects
The adverse-effect profile is recognisably that of the GLP-1 class and is dominated by gastrointestinal events: nausea, constipation, diarrhoea, vomiting, dyspepsia and abdominal pain were the most commonly reported. This is consistent with the mechanism rather than a surprise finding.
Availability in the UK
Authorisation is not the same as NHS funding. Foundayo is licensed but is not currently available through the NHS; that decision follows a separate appraisal by the National Institute for Health and Care Excellence. NICE first expected to publish its guidance on 18 November 2026; it now expects to on 27 January 2027 (NICE, checked 21 November 2026). Until the NHS funds it, access in the UK is through private prescription.
Quick reference
| Orforglipron (Foundayo) | Retatrutide | |
|---|---|---|
| Molecule type | Non-peptide small molecule | 39-residue peptide |
| Receptors | GLP-1 only | GIP / GLP-1 / glucagon |
| Route | Oral tablet, once daily | Subcutaneous, once weekly (trials) |
| UK status | Authorised 10 Aug 2026 | Investigational (not authorised) |
| Available on NHS | No (NICE guidance pending) | No |
Frequently asked questions
Is orforglipron a peptide?
No. It is a small molecule with no peptide bonds. That is the single most important technical fact about it and the reason it survives the stomach without an absorption enhancer.
Can I get Foundayo on the NHS?
Not at the time of writing. It holds a UK marketing authorisation, and NHS funding depends on NICE, whose guidance is now expected on 27 January 2027 (it was first due on 18 November 2026).
Does this approval change retatrutide's status?
No. Retatrutide remains investigational and is not authorised by the MHRA, EMA or FDA. The two compounds are at completely different regulatory stages.
Is orforglipron the first oral GLP-1?
It is not the first oral GLP-1 medicine (oral semaglutide preceded it) but it is the first oral GLP-1 agonist that is not a peptide, and the first authorised in Europe without food and water restrictions.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- RefMHRA approves orforglipron: The Pharmaceutical Journalpharmaceutical-journal.com
- RefUK first in Europe to authorise orforglipron. Drug Discovery Worldddw-online.com
- RefUK Becomes First in Europe to Approve New GLP-1 Pill. Medscapemedscape.com
- RefNICE: Orforglipron for managing overweight and obesity (GID-TA11650)nice.org.uk
- RefMHRA: Medicines and Healthcare products Regulatory Agencygov.uk
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- What Is Orforglipron? Structure, Mechanism and StatusOrforglipron is a non-peptide oral GLP-1 receptor agonist from Eli Lilly, authorised in the UK as Foundayo. Its structure, allosteric binding mode and status.
- Small Molecule vs Peptide: What Orforglipron ChangesOrforglipron is the first non-peptide GLP-1 agonist authorised in Europe. How small-molecule and peptide agonists differ in binding, stability and effect size.
- Why Peptides Cannot Normally Be Taken OrallyGastric acid, proteases and poor membrane permeability destroy oral peptides. How SNAC and absorption enhancers work, and why orforglipron needs neither.
- Retatrutide TRIUMPH-1: The Phase 3 ResultsTRIUMPH-1 reported mean weight reduction of 28.3% at 80 weeks on 12 mg retatrutide, and 30.3% at 104 weeks. Full dose-arm figures and adverse events.
- Retatrutide TRIUMPH-2 and TRIUMPH-3: What They AddedTRIUMPH-2 and TRIUMPH-3 reported in July 2026, covering type 2 diabetes and cardiovascular disease. Results, context and the remaining readouts.